Qiuqu Zhao
Research Subjects
Qiuqu Zhao has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
A Thomas
Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA 27710
1 shared publicationA. Patnaik
Medical Oncology, South Texas Accelerated Research Therapeutics, San Antonio
1 shared publicationA. Ribas
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
1 shared publication- Adil Daud
Department of Medicine University of California San Francisco California USA
1 shared publication - Anthony Michael Joshua
Kinghorn Cancer Centre, St Vincent's Hospital Sydney Australia
1 shared publication C Cheng
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 31 January 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (4) , 582-588
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan–Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2–30.4) and 38.6 months (95% CI, 27.2–not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8–11.1) and 16.9 months (95% CI, 9.3–35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. ClinicalTrials.gov, NCT01295827.
- 31 January 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (4) , 582-588
Top Cited PapersOpen AccessFive-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan–Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2–30.4) and 38.6 months (95% CI, 27.2–not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8–11.1) and 16.9 months (95% CI, 9.3–35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. ClinicalTrials.gov, NCT01295827.
- 1 June 2011
- Published by Wiley in Medical Physics
- Vol. 38 (6Part35) , 3866-3867
TH-E-BRB-04: Comparing the Effects of Tumor Motion Patterns and Beam Delivery Timing Between Scattering and Uniform Scanning Proton Beam
- 1 June 2011
- Published by Wiley in Medical Physics
- Vol. 38 (6Part35) , 3866-3867
TH-E-BRB-04: Comparing the Effects of Tumor Motion Patterns and Beam Delivery Timing Between Scattering and Uniform Scanning Proton Beam
- 1 November 2010
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 250 (1) , 012035
Determination of the depth dose distribution of proton beam using PRESAGETMdosimeter
PRESAGETM dosimeter dosimeter has been proved useful for 3D dosimetry in conventional photon therapy and IMRT [1–5]. Our objective is to examine the use of PRESAGETM dosimeter for verification of depth dose distribution in proton beam therapy. Three PRESAGETM samples were irradiated with a 79 MeV un-modulated proton beam. Percent depth dose profile measured from the PRESAGETM dosimeter is compared with data obtained in a water phantom using a parallel plate Advanced Markus chamber. The Bragg-peak position determined from the PRESAGETM is within 2 mm compared to measurements in water. PRESAGETM shows a highly linear response to proton dose. However, PRESAGETM also reveals an underdosage around the Bragg peak position due to LET effects. Depth scaling factor and quenching correction factor need further investigation. Our initial result shows that PRESAGETM has promising dosimetric characteristics that could be suitable for proton beam dosimetry.
- 1 November 2010
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 250 (1) , 012035
Determination of the depth dose distribution of proton beam using PRESAGETMdosimeter
PRESAGETM dosimeter dosimeter has been proved useful for 3D dosimetry in conventional photon therapy and IMRT [1–5]. Our objective is to examine the use of PRESAGETM dosimeter for verification of depth dose distribution in proton beam therapy. Three PRESAGETM samples were irradiated with a 79 MeV un-modulated proton beam. Percent depth dose profile measured from the PRESAGETM dosimeter is compared with data obtained in a water phantom using a parallel plate Advanced Markus chamber. The Bragg-peak position determined from the PRESAGETM is within 2 mm compared to measurements in water. PRESAGETM shows a highly linear response to proton dose. However, PRESAGETM also reveals an underdosage around the Bragg peak position due to LET effects. Depth scaling factor and quenching correction factor need further investigation. Our initial result shows that PRESAGETM has promising dosimetric characteristics that could be suitable for proton beam dosimetry.
- 1 September 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 72 (1) , S604-S605
Dosimetric Variability in Lung Cancer IMRT/SBRT among Institutions with Identical Treatment Planning Systems
- 1 September 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 72 (1) , S604-S605
Dosimetric Variability in Lung Cancer IMRT/SBRT among Institutions with Identical Treatment Planning Systems
- 1 June 2005
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 205 (2) , 188-200
Alteration at translational but not transcriptional level of transferrin receptor expression following manganese exposure at the blood–CSF barrier in vitro
- 1 June 2005
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 205 (2) , 188-200
Alteration at translational but not transcriptional level of transferrin receptor expression following manganese exposure at the blood–CSF barrier in vitro
- Open Access
- 1 June 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (6) , 2510-2511
In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis
Doripenem 50% inhibitory concentrations (MIC 50 ) and 90% inhibitory concentrations (MIC 90 ) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa ( n = 200 strains), nonmucoid P. aeruginosa ( n = 200), and Burkholderia cepacia complex ( n = 200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 μg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.
- 1 June 2005
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (6) , 2510-2511
Open AccessIn Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis
Doripenem 50% inhibitory concentrations (MIC 50 ) and 90% inhibitory concentrations (MIC 90 ) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa ( n = 200 strains), nonmucoid P. aeruginosa ( n = 200), and Burkholderia cepacia complex ( n = 200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 μg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.
- 1 December 2002
- Published by Elsevier in Brain Research
- Vol. 958 (2) , 371-380
Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus
- 1 December 2002
- Published by Elsevier in Brain Research
- Vol. 958 (2) , 371-380
Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus